Precision BioSciences to Report Third Quarter 2022 Financial Results on November 8, 2022
November 02 2022 - 7:00AM
Business Wire
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage
gene editing company developing ARCUS®-based ex vivo allogeneic CAR
T and in vivo gene editing therapies, today announced that it will
publish financial results for the third quarter 2022 and provide a
business update on November 8, 2022.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology
company dedicated to improving life (DTIL) with its novel and
proprietary ARCUS® genome editing platform. ARCUS is a highly
specific and versatile genome editing platform that was designed
with therapeutic safety, delivery, and control in mind. Using
ARCUS, the Company’s pipeline consists of multiple “off-the-shelf”
CAR T immunotherapy clinical candidates and several in vivo gene
editing therapy candidates designed to cure genetic and infectious
diseases where no adequate treatments exist. For more information
about Precision BioSciences please visit
www.precisionbiosciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221102005105/en/
Investor Contact: Mei Burris Director, Investor Relations
and Finance Mei.Burris@precisionbiosciences.com
Media Contact: Maurissa Messier Senior Director,
Corporate Communications
Maurissa.Messier@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Sep 2023 to Sep 2024